SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Synchrony Financial issued 500,000 depositary shares representing Series C Preferred Stock (7.250% Fixed Rate Reset Non-Cumulative Perpetual) on June 5, 2026 pursuant to an underwriting agreement dated June 2, 2026. The offering was registered and resulted in material shareholder dilution and capital raising.
View raw filing on EDGAR →BlackRock Monticello entered into two material financing arrangements: a $100M credit facility with ConnectOne Bank (expandable to $150M) and a $250M repurchase agreement with Nomura. These facilities are designed to finance the acquisition of eligible commercial real estate loans, which is material to the REIT's operations and asset acquisition strategy.
View raw filing on EDGAR →Santander Holdings USA completed a public offering of $2.5 billion in aggregate principal amount of senior notes across three tranches (2030, 2032, and 2037 maturities). While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the more specific event categories (ma_activity applies to acquisitions/dispositions/mergers, not routine debt offerings; dilutive_issuance applies to equity securities, not debt). The disclosure is material but represents a financing event outside the standard taxonomy.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from Procore's June 4, 2026 annual meeting. The filing reports final voting tallies for three proposals: election of three Class II directors (Courtemanche, Bueker, and Caldwell), ratification of PwC as independent auditor, and an advisory vote on named executive officer compensation. All three proposals passed, with detailed vote counts provided for each.
View raw filing on EDGAR →The filing discloses that Standard BioTools has regained compliance with Nasdaq's minimum bid price requirement (Rule 5450(a)(1)) after previously falling below $1.00 per share for 30 consecutive business days on April 20, 2026. While the current disclosure is positive (resolution of the delisting risk), the underlying event—the prior non-compliance notice and threat of delisting—is material to investors and directly relates to the delisting_risk category. The company's ability to maintain listing is a fundamental concern for equity investors.
View raw filing on EDGAR →The filing discloses the completion of a merger between Cubs Merger Sub, Inc. (a wholly owned subsidiary of Devon) and Coterra Energy Inc., with the Certificate of Designations for Coterra Preferred Stock amended to provide for conversion into Devon common stock. This represents a material acquisition/change of control event, evidenced by the merger consummation and the integration of Coterra's preferred stock into Devon's capital structure.
View raw filing on EDGAR →Mr. Jordan Krugman's resignation from all positions at Invesco Capital Management LLC and its affiliates, including his position as a member of the Board of Managers of the Sponsor, effective August 3, 2026, constitutes a departure of an officer/manager. The disclosure is made under Item 5.02(b) and explicitly states the resignation notice and effective date, which are hallmarks of an executive departure event.
View raw filing on EDGAR →Mr. Jordan Krugman resigned from all positions at Invesco Capital Management LLC, the Managing Owner of the fund, including his position as a member of the Board of Managers, effective August 3, 2026. This is a clear executive departure disclosure under Item 5.02(b), and the resignation of a board member and officer of the managing owner is material to investors in the fund.
View raw filing on EDGAR →Mr. Jordan Krugman resigned from all positions at Invesco Specialized Products, LLC and its affiliates, including his position as a member of the Board of Managers of the Sponsor, effective August 3, 2026. This is a clear executive departure disclosure under Item 5.02, and the resignation of a board member from the Sponsor managing the Trust is material to investors in the fund.
View raw filing on EDGAR →Mr. Jordan Krugman resigned from all positions at Invesco Specialized Products, LLC and its affiliates, including his position as a member of the Board of Managers of the Sponsor, effective August 3, 2026. This is a clear executive departure disclosure under Item 5.02, and the resignation of a board member at the Sponsor managing the Trust is material to investors in the fund.
View raw filing on EDGAR →Mr. Jordan Krugman resigned from all positions at Invesco Specialized Products, LLC and its affiliates, including his position as a member of the Board of Managers of the Sponsor, effective August 3, 2026. This is a clear executive departure disclosure under Item 5.02, and the resignation of a board member at the Sponsor managing the Trust is material to investors in the fund.
View raw filing on EDGAR →Mr. Jordan Krugman's resignation from all positions at Invesco Capital Management LLC and its affiliates, including his role as a member of the Board of Managers of the Sponsor, effective August 3, 2026, constitutes a departure of a key officer. The disclosure explicitly states the resignation notice and effective date, which is the hallmark of an exec_departure event under Item 5.02(b).
View raw filing on EDGAR →Mr. Jordan Krugman resigned from all positions at Invesco Specialized Products, LLC (the Sponsor) and its affiliates, including his position as a member of the Board of Managers, effective August 3, 2026. This is a clear executive departure disclosure under Item 5.02, as the principal action is a named officer leaving his roles. The departure of a board member and officer at the Sponsor is material to investors in the Trust.
View raw filing on EDGAR →Mr. Jordan Krugman resigned from all positions at Invesco Specialized Products, LLC (the Sponsor) and its affiliates, including his position as a member of the Board of Managers, effective August 3, 2026. This is a clear executive departure disclosure under Item 5.02, as the principal action is a named officer leaving his roles. The departure of a board member and officer at the Sponsor is material to investors in the Trust.
View raw filing on EDGAR →Mr. Jordan Krugman resigned from all positions at Invesco Specialized Products, LLC (the Sponsor) and its affiliates, including his position as a member of the Board of Managers, effective August 3, 2026. This is a clear executive departure disclosure under Item 5.02, as the principal action is a named officer leaving his roles. The departure of a board member and officer at the Sponsor is material to investors in the Trust.
View raw filing on EDGAR →Mr. Jordan Krugman's resignation from all positions at Invesco Capital Management LLC and its affiliates, including his position as a member of the Board of Managers of the Sponsor, effective August 3, 2026, constitutes a departure of an officer/manager. The disclosure is material as it affects the governance and management structure of the fund's sponsor, which would be relevant to investors in the ETF.
View raw filing on EDGAR →Mr. Jordan Krugman resigned from all positions at Invesco Capital Management LLC, including his position as a member of the Board of Managers of the Managing Owner, effective August 3, 2026. This is a clear departure of an officer/manager from the registrant's managing owner, disclosed under Item 5.02(b), and would be material to investors in the fund.
View raw filing on EDGAR →MSD Investment Corp. entered into Amendment No. 1 to its Senior Secured Credit Agreement, increasing the limitation on Shorter Term Unsecured Indebtedness from $200 million to $600 million, thereby expanding its borrowing capacity under the facility.
View raw filing on EDGAR →Mr. Jordan Krugman resigned from all positions at Invesco Capital Management LLC, including his role as a member of the Board of Managers of the Managing Owner, effective August 3, 2026. This is a clear departure of an officer/manager from the registrant's managing owner, disclosed under Item 5.02(b), and would materially affect investor assessment of the fund's governance and management continuity.
View raw filing on EDGAR →This Item 5.07 filing discloses the final results of Arcturus Therapeutics' 2026 annual stockholder meeting held on June 5, 2026, including voting outcomes on three proposals: election of eight directors, advisory approval of named executive officer compensation ("say-on-pay"), and ratification of Deloitte as independent auditor. All three proposals passed with substantial majorities, and the detailed vote tallies are provided for each director nominee and proposal.
View raw filing on EDGAR →The filing discloses a merger transaction (the "Merger") with Serra Verde Group (SVG) that is contemplated and in progress. USAR filed a preliminary proxy statement on Schedule 14A on May 13, 2026, and is now filing updated pro forma condensed combined financial statements for the three months ended March 31, 2026 and the year ended December 31, 2025 "giving effect to the Merger." The disclosure explicitly references the merger agreement, stockholder voting requirements, and the definitive proxy statement to follow, all hallmarks of a material acquisition or change of control transaction under Item 8.01 (Other Events) in connection with M&A activity.
View raw filing on EDGAR →Keel Infrastructure announced the pricing of a $400 million offering of convertible senior notes due 2032, with an additional $58 million option for initial purchasers. Convertible notes are inherently dilutive securities that create equity exposure and potential shareholder dilution upon conversion. The substantial size ($400–458 million) and the company's stated use of proceeds for capital projects and capped call transactions make this a material capital-raising event affecting the equity base.
View raw filing on EDGAR →The disclosure announces a postponement of an extraordinary general meeting (EGM) from June 9 to June 12, 2026, to seek shareholder approval for extending the Company's initial business combination deadline from June 12, 2026 to June 12, 2027. While this involves a shareholder vote, the core event is the extension of the business combination deadline itself—a material corporate action for a SPAC that affects the timeline for completing its fundamental purpose. This does not fit cleanly into shareholder_vote_results (which typically reports vote outcomes, not the scheduling of future votes) nor into other specific categories, making other_material the most appropriate classification.
View raw filing on EDGAR →Ms. Lisa Locklear, Chief Financial Officer of Longeveron Inc., informed management on June 1, 2026 of her decision to step down, effective July 10, 2026. While the filing also mentions the anticipated elevation of Marie Washburn to CFO, the principal disclosed action is the departure of a named executive officer (CFO). The resignation was not due to disagreement and is material to investors assessing management continuity.
View raw filing on EDGAR →PMGC Holdings' subsidiary NorthStrive Defense Tech entered into two material definitive agreements with Florida State University Research Foundation: (1) an exclusive, worldwide patent license covering aerospace and defense technologies with tiered royalties and annual maintenance fees, and (2) a $490,657 research funding agreement. These agreements represent entry into material commercial arrangements that would affect a reasonable investor's assessment of the company's strategic direction, IP portfolio, and R&D commitments in the defense sector.
View raw filing on EDGAR →The filing discloses termination of an at-the-market (ATM) equity issuance agreement with Maxim Group LLC. While the Item 1.02 heading emphasizes termination, the material substance is the prior issuance of 3,280,927 ordinary shares for approximately $4.4 million in net proceeds under this dilutive equity facility. ATM offerings are a classic signal of capital-raising activity at smaller issuers and represent material dilution to existing shareholders.
View raw filing on EDGAR →Theresa Greco, Chief Commercial Officer, is departing OptimizeRx Corporation effective June 15, 2026, pursuant to a separation agreement executed June 1, 2026. While the filing also discloses severance and advisory arrangement terms, the principal disclosed action is the departure of a named executive officer from her role, making exec_departure the most salient classification. The departure of a CCO is material to investors' assessment of the company's commercial leadership and strategy.
View raw filing on EDGAR →Eric Haynor, the Chief Operating Officer, resigned effective June 5, 2026. The filing explicitly states his resignation and confirms it was not due to disagreement with the Company. This is a departure of a named executive officer and would materially affect investor assessment of the registrant's leadership and operational continuity.
View raw filing on EDGAR →Henry Liu resigned as Co-Chief Executive Officer effective June 2, 2026, with no disagreement cited. The filing discloses under Item 5.02 that following his departure, Yang Li now serves as sole CEO. This is a material executive departure affecting the company's leadership structure.
View raw filing on EDGAR →The Company entered into Amendment No. 2 to increase its at-the-market (ATM) offering capacity from $100 million to $150 million in common stock, with a concurrent $50 million shelf registration. ATM offerings are unregistered equity issuances that create dilution risk for existing shareholders and are a material capital-raising event, particularly for smaller biotechnology companies like Unicycive.
View raw filing on EDGAR →Tavia Acquisition Corp. issued an unsecured promissory note of up to $540,000 to its sponsor to fund contributions to the trust account in connection with the Company's initial public offering and anticipated initial business combination.
View raw filing on EDGAR →The filing discloses creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, though the substantive details of the obligation are not fully provided in the available excerpts.
View raw filing on EDGAR →Shareholders redeemed 7,167,225 Ordinary Shares at approximately $10.66 per share ($76.4 million aggregate), reducing outstanding shares from approximately 15.9 million to 8.75 million and leaving $46.2 million in the Trust Account, materially affecting the Company's capital structure and cash position.
View raw filing on EDGAR →The filing discloses results of Nektar Therapeutics' Annual Meeting of Stockholders held on June 4, 2026, under Item 5.07. Four proposals were voted on: election of director Howard W. Robin (13,164,879 for, 4,975,288 against), approval of a 3,000,000 share increase to the 2017 Performance Incentive Plan (13,160,661 for, 4,902,925 against), ratification of Ernst & Young LLP as auditor (22,591,556 for, 118,592 against), and approval of executive compensation (18,154,226 for, 161,005 against). All proposals passed with substantial majorities, making this a standard shareholder vote results disclosure.
View raw filing on EDGAR →The filing discloses the resignation of two senior executives effective immediately: Christopher J. Porcelli (General Counsel, Chief People Officer, and Corporate Secretary) and Brian Brady (non-executive Chairman and Board member). These are material departures of named officers and a director that would affect investor assessment of the company's governance and leadership continuity. The immediate effective date and lack of transition details heighten materiality.
View raw filing on EDGAR →Mountain Lake Acquisition Corp. shareholders voted on June 4, 2026, approving five material proposals including the business combination agreement with Avalanche Treasury Corporation, the merger, domestication, organizational documents, Nasdaq listing, and director election.
View raw filing on EDGAR →The Sponsor distributed 2,781,776 Class B shares to its constituent members, including 478,010 shares each to CEO Paul Grinberg, CFO Douglas Horlick, and Director Jaime Vieser, representing a material change in share ownership and executive equity interests.
View raw filing on EDGAR →BiomX issued 1,013,637 restricted shares of common stock upon partial conversion of a convertible promissory note from Mandragola Ltd., with the shares issued in reliance on Section 4(a)(2) of the Securities Act without registration. This is a classic unregistered equity issuance tied to debt conversion, representing dilution to existing shareholders. The concurrent warrant grant (2,000,000 shares at $12.00 exercise price) further evidences the dilutive financing structure. Item 3.02 disclosure and the explicit reliance on Section 4(a)(2) exemption confirm this is a material unregistered sale of equity securities.
View raw filing on EDGAR →Item 8.01 references a press release disclosed under Item 2.02 (Results of Operations and Financial Condition) and attached as Exhibit 99.1. This structure is typical for earnings releases, where the substantive financial disclosure occurs under Item 2.02 and Item 8.01 merely furnishes the exhibit. The cross-reference to Item 2.02 strongly indicates this is an earnings release.
View raw filing on EDGAR →Nasdaq has issued a staff determination letter notifying Ribbon Acquisition Corp. of its decision to delist the Company's securities due to failure to pay $75,000 in required listing fees under Nasdaq Rule 5250(f). The Company intends to appeal but acknowledges "there can be no assurance that the Company will be successful in maintaining the listing of its securities on Nasdaq." This is a direct delisting notice triggering Item 3.01 disclosure.
View raw filing on EDGAR →Xos completed a registered direct offering of 1,090,910 shares of common stock at $5.50 per share, raising approximately $6.0 million in gross proceeds on June 5, 2026. While technically registered under the S-3 shelf, this is a direct equity issuance that dilutes existing shareholders and represents a material capital-raising event that would affect investor assessment of the company's financial position and ownership structure.
View raw filing on EDGAR →Long Table Growth Corp. completed its initial public offering on June 5, 2026, raising $172.5 million in gross proceeds from the sale of 17.25 million units and entering into multiple material definitive agreements (Underwriting Agreement, Warrant Agreement, Investment Management Trust Agreement, Registration Rights Agreement, and Private Placement Warrants Purchase Agreement) in connection with the IPO.
View raw filing on EDGAR →Long Table Growth Corp. completed a private placement of 3,600,000 warrants for $3.6 million pursuant to Section 4(a)(2) exemption from registration, executed simultaneously with the IPO closing.
View raw filing on EDGAR →Three independent directors—Rich Riley, Benjamin Doramus, and Amir Husain—were appointed to the Board effective June 3, 2026, in connection with the Company's IPO, with assignments to the Audit and Compensation Committees.
View raw filing on EDGAR →Long Table Growth Corp. adopted an Amended and Restated Memorandum and Articles of Association effective June 3, 2026, in connection with the Company's IPO.
View raw filing on EDGAR →The filing discloses both the departure of Mr. Leung and the appointment of Mr. Rosales as acting Chief Financial Officer. While both events are mentioned, the principal action centers on the appointment of a new CFO to fill the vacancy. The appointment of a named executive officer to a C-suite position is material to investors assessing management continuity and financial oversight. The "acting" designation introduces some ambiguity about permanence, which moderates confidence slightly.
View raw filing on EDGAR →The filing discloses a private placement of Series A Convertible Preferred Stock and warrants under Section 4(a)(2) and Regulation D Rule 506(c). At the first closing, the Company issued 1,143 Units for $1.143 million in gross proceeds, with the offering structured to raise up to $5 million plus an additional $5 million overallotment option. The Preferred Shares are convertible at $0.05 per share and the Warrants are exercisable at $0.0625 per share, both creating significant dilution to existing shareholders. Item 3.02 explicitly confirms this is an unregistered sale of equity securities.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of CVR Energy's 2026 Annual Meeting of Stockholders held on June 4, 2026, including voting outcomes on three proposals: election of ten directors, advisory vote on named executive officer compensation, and ratification of Grant Thornton as independent auditor. The filing provides detailed vote tallies for each director and proposal, which is the core content required for shareholder_vote_results classification.
View raw filing on EDGAR →iRhythm disclosed a binding settlement agreement resolving a putative class action securities litigation for $45 million. The settlement is material to investors as it eliminates significant litigation risk and financial exposure, with the company expecting insurance to cover a majority of the payment. The disclosure explicitly addresses the resolution of previously-disclosed litigation and its financial impact.
View raw filing on EDGAR →Alka Chaubey, Ph.D., Chief Medical Officer of Bionano Genomics, resigned effective July 5, 2026. This is a clear departure of a named executive officer disclosed under Item 5.02, and the departure of a CMO—a senior leadership position—is material to investors' assessment of the company's medical and scientific direction.
View raw filing on EDGAR →